Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment

Hepatocellular carcinoma (HCC) is the most common type of primary hepatic malignancy. HCC is one of the leading causes of cancer deaths worldwide. The oral multi-tyrosine kinase inhibitor Sorafenib is the standard first-line therapy in patients with advanced unresectable HCC. Despite the significant...

Descripción completa

Detalles Bibliográficos
Autores principales: Shrestha, Ritu, Prithviraj, Prashanth, Bridle, Kim R., Crawford, Darrell H. G., Jayachandran, Aparna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123871/
https://www.ncbi.nlm.nih.gov/pubmed/33925488
http://dx.doi.org/10.3390/jcm10091889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123871/
https://www.ncbi.nlm.nih.gov/pubmed/33925488
http://dx.doi.org/10.3390/jcm10091889

Ejemplares similares